Pharmaids Pharmaceuticals appoints internal auditor for FY 2026-27

1 min read     Updated on 30 Jun 2026, 09:27 PM
scanx
Reviewed by
Suketu GScanX News Team
AI Summary

Pharmaids Pharmaceuticals Limited appointed M/s. V Mahendra & Associates Chartered Accountants as internal auditor for FY 2026-27, approved by the Board on June 30, 2026. The firm has over 23 years of experience in compliance and internal controls. The disclosure was made under SEBI Regulation 30.

powered bylight_fuzz_icon
44380625

*this image is generated using AI for illustrative purposes only.

Pharmaids Pharmaceuticals Limited has appointed M/s. V Mahendra & Associates Chartered Accountants as its internal auditor for the financial year 2026-27. The Board of Directors approved the appointment on June 30, 2026, following the recommendation of the Audit Committee. The firm will oversee internal audit functions to ensure compliance and strengthen internal controls.

The appointment was disclosed to BSE Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that the information is available on its website. The decision aligns with the requirements of SEBI Master Circular dated January 30, 2026.

M/s. V Mahendra & Associates is a Chartered Accountant firm with over 23 years of professional experience. The firm specializes in assisting corporate entities with statutory compliance, internal controls, financial reporting systems, and operational efficiency. Its registration number is 025356S.

The table below outlines the key details of the appointment:

Sl. No. Particulars Details
1 Reason for change Appointment of M/s. V Mahendra & Associates Chartered Accountants (FRN: 025356S) as Internal Auditors for FY 2026-27.
2 Date of appointment June 30, 2026
3 Brief Profile Chartered Accountant firm with over 23 years of experience, focusing on compliance, internal controls, and operational efficiency.

The disclosure was signed by Prasanna Subramanya Bhat, Company Secretary & Compliance Officer of Pharmaids Pharmaceuticals Limited . The appointment is effective immediately for the specified financial year.

Historical Stock Returns for Pharmaids Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
+2.76%-0.23%+18.93%-26.35%-42.72%+151.73%

What specific areas of operational efficiency does Pharmaids Pharmaceuticals aim to improve with this new internal auditor?

How might the appointment impact the company's compliance posture ahead of the upcoming financial year?

Will the new internal auditor collaborate with external auditors to enhance financial reporting transparency?

Pharmaids Pharmaceuticals
View Company Insights
View All News
like16
dislike

Pharmaids Pharmaceuticals VP resigns citing personal reasons

1 min read     Updated on 25 Jun 2026, 07:09 PM
scanx
Reviewed by
Shriram SScanX News Team
AI Summary

Pharmaids Pharmaceuticals Limited accepted the resignation of Dr. Jagadeesh M N as Vice President – Discovery Services effective June 25, 2026, due to personal reasons. The disclosure was filed with BSE under Regulation 30 of the SEBI Listing Regulations.

powered bylight_fuzz_icon
43940351

*this image is generated using AI for illustrative purposes only.

Pharmaids Pharmaceuticals Limited has accepted the resignation of Dr. Jagadeesh M N from the position of Vice President – Discovery Services. The resignation, effective from the close of business hours on June 25, 2026, was submitted due to personal reasons. This development impacts the company's senior management structure within its discovery services division.

The disclosure was made to BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that the necessary details, including the resignation letter, have been submitted as required under the regulations read with the SEBI Master Circular dated January 30, 2026.

Venu Madhava Kaparthy, Whole-time Director of Pharmaids Pharmaceuticals Limited, signed the regulatory filing. The resignation letter addressed to the Board of Directors expressed gratitude to the board and wished the company well for the future. The information has been made available on the company's official website.

The following table outlines the key details of the management change:

Particulars Details
Reason for change Resignation due to personal reasons
Date of cessation June 25, 2026
Brief profile Not Applicable
Relationship disclosure Not Applicable

Historical Stock Returns for Pharmaids Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
+2.76%-0.23%+18.93%-26.35%-42.72%+151.73%

Who will be appointed to replace Dr. Jagadeesh M N, and how will this transition affect ongoing discovery projects?

What is the timeline for announcing a successor, and will an interim leadership structure be implemented?

How might this leadership change impact Pharmaids' strategic priorities in the discovery services division?

Pharmaids Pharmaceuticals
View Company Insights
View All News
like19
dislike

More News on Pharmaids Pharmaceuticals

Must Read Next

Earnings

Corporate Actions

Stocks

1 Year Returns:-42.72%